4 research outputs found
Modulation of Activity Profiles for Largazole-Based HDAC Inhibitors through Alteration of Prodrug Properties
Largazole is a potent and class I-selective
histone deacetylase
(HDAC) inhibitor purified from marine cyanobacteria and was demonstrated
to possess antitumor activity. Largazole employs a unique prodrug
strategy, via a thioester moiety, to liberate the bioactive species
largazole thiol. Here we report alternate prodrug strategies to modulate
the pharmacokinetic and pharmacodynamics profiles of new largazole-based
compounds. The in vitro effects of largazole analogues on cancer cell
proliferation and enzymatic activities of purified HDACs were comparable
to the natural product. However, in vitro and in vivo histone hyperacetylation
in HCT116 cells and implanted tumors, respectively, showed differences,
particularly in the onset of action and oral bioavailability. These
results indicate that, by employing a different approach to disguise
the āwarheadā moiety, the functional consequence of
these prodrugs can be significantly modulated. Our data corroborate
the role of the pharmacokinetic properties of this class of compounds
to elicit the desired and timely functional response
Manipulating JNK Signaling with (ā)-Zuonin A
Recently, in a virtual screening strategy to identify
new compounds
targeting the D-recruitment site (DRS) of the c-Jun N-terminal kinases
(JNKs), we identified the natural product (ā)-zuonin A. Here
we report the asymmetric synthesis of (ā)-zuonin A and its
enantiomer (+)-zuonin A. A kinetic analysis for the inhibition of
c-Jun phosphorylation by (ā)-zuonin A revealed a mechanism
of partial competitive inhibition. Its binding is proposed to weaken
the interaction of c-Jun to JNK by approximately 5-fold, without affecting
the efficiency of phosphorylation within the complex. (ā)-Zuonin
A inhibits the ability of both MKK4 and MKK7 to phosphorylate and
activate JNK. The binding site of (ā)-zuonin A is predicted
by docking and molecular dynamics simulation to be located in the
DRS of JNK. (+)-Zuonin A also binds JNK but barely impedes the binding
of c-Jun. (ā)-Zuonin A inhibits the activation of JNK, as well
as the phosphorylation of c-Jun in anisomycin-treated HEK293 cells,
with the inhibition of JNK activation being more pronounced. (ā)-Zuonin
A also inhibits events associated with constitutive JNK2 activity,
including c-Jun phosphorylation, basal Akt activation, and MDA-MB-231
cell migration. Mutations in the predicted binding site for (ā)-zuonin
A can render it significantly more or less sensitive to inhibition
than wild type JNK2, allowing for the design of potential chemical
genetic experiments. These studies suggest that the biological activity
reported for other lignans, such as saucerneol F and zuonin B, may
be the result of their ability to impede proteināprotein interactions
within MAPK cascades
Manipulating JNK Signaling with (ā)-Zuonin A
Recently, in a virtual screening strategy to identify
new compounds
targeting the D-recruitment site (DRS) of the c-Jun N-terminal kinases
(JNKs), we identified the natural product (ā)-zuonin A. Here
we report the asymmetric synthesis of (ā)-zuonin A and its
enantiomer (+)-zuonin A. A kinetic analysis for the inhibition of
c-Jun phosphorylation by (ā)-zuonin A revealed a mechanism
of partial competitive inhibition. Its binding is proposed to weaken
the interaction of c-Jun to JNK by approximately 5-fold, without affecting
the efficiency of phosphorylation within the complex. (ā)-Zuonin
A inhibits the ability of both MKK4 and MKK7 to phosphorylate and
activate JNK. The binding site of (ā)-zuonin A is predicted
by docking and molecular dynamics simulation to be located in the
DRS of JNK. (+)-Zuonin A also binds JNK but barely impedes the binding
of c-Jun. (ā)-Zuonin A inhibits the activation of JNK, as well
as the phosphorylation of c-Jun in anisomycin-treated HEK293 cells,
with the inhibition of JNK activation being more pronounced. (ā)-Zuonin
A also inhibits events associated with constitutive JNK2 activity,
including c-Jun phosphorylation, basal Akt activation, and MDA-MB-231
cell migration. Mutations in the predicted binding site for (ā)-zuonin
A can render it significantly more or less sensitive to inhibition
than wild type JNK2, allowing for the design of potential chemical
genetic experiments. These studies suggest that the biological activity
reported for other lignans, such as saucerneol F and zuonin B, may
be the result of their ability to impede proteināprotein interactions
within MAPK cascades
From in Silico Discovery to Intracellular Activity: Targeting JNKāProtein Interactions with Small Molecules
The JNKāJIP1 interaction represents an attractive
target
for the selective inhibition of JNK-mediated signaling. We report
a virtual screening (VS) workflow, based on a combination of three-dimensional
shape and electrostatic similarity, to discover novel scaffolds for
the development of non-ATP competitive inhibitors of JNK targeting
the JNKāJIP interaction. Of 352 (0.13%) compounds selected
from the NCI Diversity Set, more than 22% registered as hits in a
biochemical kinase assay. Several compounds discovered to inhibit
JNK activity under standard kinase assay conditions also impeded JNK
activity in HEK293 cells. These studies led to the discovery that
the lignan (ā)-zuonin A inhibits JNKāprotein interactions
with a selectivity of 100-fold over ERK2 and p38 MAPKĪ±. These
results demonstrate the utility of a virtual screening protocol to
identify novel scaffolds for highly selective, cell-permeable inhibitors
of JNKāprotein interactions